EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Sacubitril/Valsartan as a Cardiac Radioprotector

Mihaela Ghita-Pettigrew, Brianna N Kerr, Kathryn H Brown, Narainrit Karuna, Kevin S Edgar, Brian Herron, Siobhan Comer, Arvin Suguna Seelan, Mark T Harbinson, Alastair Greystoke, Corinne Faivre-Finn, David J Grieve und 3 weitere

International Journal of Radiation Oncology*Biology*Physics · 2026-08 · 125 (5) · 1506-1511

DOI: 10.1016/j.ijrobp.2026.02.203 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2026-08. Verfasst von Mihaela Ghita-Pettigrew und 14 weiteren Autor:innen. Beteiligte Einrichtung: The Johnston Cancer Research Centre, Queen's University Belfast, Belfast, United Kingdom. Hauptthemen laut MEDLINE: Atrial Natriuretic Factor, Tetrazoles, Aminobutyrates, Radiation-Protective Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UKRI Medical Research Council, AstraZeneca, Cancer Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: The role of the natriuretic peptides in radiation heart injury (RHI) has not been thoroughly examined. Pharmacologic modulation of the natriuretic peptide system with sacubitril/valsartan (sac/val) has led to improvements in heart failure therapy, and preliminary data suggest that RHI is associated with decreased atrial natriuretic peptide (ANP). In this study, we assessed sac/val as a radioprotector in a partial-heart irradiation mouse model and explored preliminary trends in patients receiving thoracic irradiation. METHODS AND MATERIALS: Female 8-10-week-old C57BL/6J mice were randomly assigned to receive sham irradiation, with or without sac/val, or irradiation with or without sac/val. The superior two-thirds of the heart was exposed to 20 Gy of x-rays using a small animal radiation research platform. Cardiac function was assessed at 10-week intervals over 30 weeks by transthoracic echocardiography and electrocardiography. Plasma levels of ANP were analyzed at 30 weeks. Small retrospective clinical series were undertaken in patients undergoing thoracic radiation therapy, to assess ANP dynamics and sac/val safety. RESULTS: At 30 weeks, irradiated mice that received sac/val exhibited a marked improvement in structural remodeling, systolic longitudinal strain, diastolic function, and electrophysiological parameters, compared with irradiated animals that did not receive sac/val. Functional sparing with sac/val was detectable as early as 10 weeks postirradiation by global longitudinal strain. Animals and patients tolerated the combination of sac/val with radiation without additional adverse effects. NT-proANP levels generally decreased among patients during thoracic radiation therapy and posttreatment NT-proANP changes were dose dependent. There was no effect on tolerability or efficacy of (chemo)radiation for patients on sac/val concurrently for heart failure. CONCLUSIONS: Sac/val attenuated structural and functional aspects of RHI and was well tolerated in animals when given with radiation. Clinical data suggest that ANP changes dynamically during radiation therapy and that sac/val is safe to take concurrently. Further investigation of sac/val as a cardiac radioprotector is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial Natriuretic FactorTetrazolesAminobutyratesRadiation-Protective AgentsHeartRadiation Injuries, ExperimentalAnimalsBiphenyl CompoundsFemaleValsartanDrug CombinationsMice, Inbred C57BLMiceHumansRandom AllocationElectrocardiographyEchocardiography

Substanzen

Biphenyl CompoundsAtrial Natriuretic FactorTetrazolesValsartansacubitril and valsartan sodium hydrate drug combinationDrug CombinationsAminobutyratesRadiation-Protective Agents

Autor:innen und Institutionen

  • The Johnston Cancer Research Centre, Queen's University Belfast, Belfast, United Kingdom.
  • Wellcome-Wolfson Institute of Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom; Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand.
  • Wellcome-Wolfson Institute of Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom.
  • Department of Histopathology, Belfast Health & Social Care Trust, Belfast, United Kingdom.
  • Cancer Centre Belfast City Hospital, Belfast Health & Social Care Trust, Belfast, United Kingdom.
  • Wellcome-Wolfson Institute of Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom; Centre for Medical Education, Queen's University Belfast, Belfast, United Kingdom.

Förderung

  • UKRI Medical Research Council
  • AstraZeneca
  • Cancer Research UK

Zitieren

APA

Ghita-Pettigrew, M., Kerr, B. N., Brown, K. H., Karuna, N., Edgar, K. S., Herron, B., Comer, S., Seelan, A. S., Harbinson, M. T., Greystoke, A., Faivre-Finn, C., Grieve, D. J., Watson, C. J., Butterworth, K. T., & Walls, G. M. (2026). Sacubitril/Valsartan as a Cardiac Radioprotector. International Journal of Radiation Oncology*Biology*Physics, 125(5), 1506-1511. https://doi.org/10.1016/j.ijrobp.2026.02.203

Vancouver

Ghita-Pettigrew M, Kerr BN, Brown KH, Karuna N, Edgar KS, Herron B, et al. Sacubitril/Valsartan as a Cardiac Radioprotector. International Journal of Radiation Oncology*Biology*Physics. 2026;125(5):1506-1511. doi:10.1016/j.ijrobp.2026.02.203

BibTeX
@article{GhitaPettigrew2026,
  author = {Ghita-Pettigrew, Mihaela and Kerr, Brianna N and Brown, Kathryn H and Karuna, Narainrit and Edgar, Kevin S and Herron, Brian and Comer, Siobhan and Seelan, Arvin Suguna and Harbinson, Mark T and Greystoke, Alastair and Faivre-Finn, Corinne and Grieve, David J and Watson, Chris J and Butterworth, Karl T and Walls, Gerard M},
  title = {Sacubitril/Valsartan as a Cardiac Radioprotector},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2026},
  volume = {125},
  number = {5},
  pages = {1506--1511},
  doi = {10.1016/j.ijrobp.2026.02.203}
}
Kostenlos starten →